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Intrarenal dopamine  
deficiency induces  
salt-sensitive hypertension
Zhang et al., J Clin Invest 2011; 121: 2845–2854; doi:10.1172/JCI57324
It has long been known that dopamine is involved in renal sodium 
excretion, but the details of its function are poorly understood. In 
addition to dopamine receptors, the kidney possesses an intrarenal 
dopaminergic system. Via multiple amino acid transporters, the 
dopamine precursor l-dihydroxyphenylalanine (l-DOPA) can be 
taken up by the proximal tubular cells either from the circulation or 
after glomerular filtration, and the aromatic amino acid decarboxy-
lase (AADC) located in these cells converts l-DOPA to dopamine. 
This might account for the finding that while circulating concentra-
tions of dopamine are normally in the picomolar range, dopamine 
levels in the kidney can reach high nanomolar concentrations. In 
addition, intrarenal dopamine production can be modulated by 
changes in salt intake, and abnormalities in dopamine produc-
tion and receptor function have been associated with hyperten-
sion in humans and in several forms of genetic hypertension in 
rodents. Because previous studies have not been able to discrimi-
nate between intrarenally and extrarenally produced dopamine in 
the regulation of kidney function, Zhang et al. developed a mouse 
with defective intrarenal dopamine production. They selectively 
deleted AADC in the kidney proximal tubules (ptAadc–/– mice) by 
crossing Aadcflox7/flox7 mice with g-GT Cre mice (the γGT promoter 
expresses Cre recombinase only in the kidney cortex). As expected, 
AADC expression in wild-type mice was largely confined to the 
renal cortex, particularly in proximal tubules, while in ptAadc–/– 
mice, AADC immunoreactivity was hardly detectable in the renal 
cortex, although AADC expression in the small intestine and in 
neurons was not different from that of wild-type mice (Figure). 
There were also no differences in brain and plasma dopamine levels, 
but kidney and urinary dopamine levels were significantly lower in 
ptAadc–/– mice. It is of great interest that the ptAadc–/– mice had 
increased expression of nephron sodium transporters, decreased 
natriuresis and diuresis in response to l-DOPA, and decreased 
medullary COX-2 expression and urinary prostaglandin E2 excre-
tion and developed salt-sensitive hypertension. In addition, they 
had increased renin expression, altered renal angiotensin II recep-
tors, and increased kidney injury in response to angiotensin II. They 
also had a substantially shorter lifespan than wild-type mice. Thus, 
decreased intrarenal dopamine subjects the kidney to unopposed 
angiotensin II action that results in hypertension and a dramatic 
decrease in longevity. This important study demonstrates the criti-
cal role of the intrarenal dopaminergic system in salt and water 
homeostasis and blood pressure control.
Juan Oliver
Rosuvastatin in diabetic 
hemodialysis patients
Holdaas et al., J Am Soc Nephrol 2011; 22: 1335–1341; doi:10.1681/
ASN.2010090987
The AURORA trial randomized patients with end-stage renal 
disease (ESRD) to rosuvastatin or placebo to assess the effect of 
rosuvastatin on the primary end point of cardiac death, nonfa-
tal myocardial infarction (MI), or fatal or nonfatal stroke.1 This 
trial failed to demonstrate an effect of treatment on this compos-
ite outcome. Holdaas et al. conducted a subgroup analysis of only 
patients with diabetes mellitus using the methods of the primary 
trial, recruiting 731 patients into the trial. Patients undergoing 
transplantation were not censored. After 3 months of therapy, low-
density lipoprotein was reduced by 38.5% in the treatment arm, 
with little change in the placebo arm. The composite end point 
of cardiac death and nonfatal MI was less frequent in the active-
treatment arm (HR 0.68, 95% CI 0.51–0.90). The primary end point 
of the AURORA trial (cardiac death, nonfatal MI, fatal or nonfatal 
stroke) demonstrated a non-significant trend of HR 0.838 (95% CI 
0.654–1.074) because of a trend toward a greater risk of stroke in the 
active-treatment arm (HR 1.65, 95% CI 0.96–2.83). Although there 
was a small number of events, this risk was particularly noteworthy 
with respect to hemorrhagic strokes (HR 5.21, 95% CI 1.17–23.27). 
Notably, the interaction between treatment arm and diabetes mel-
litus was highly significant with respect to cardiac events.
The trials of statin therapy among people with ESRD conflict 
with those among people with chronic kidney disease (CKD). The 
Study of Heart and Renal Protection (SHARP) demonstrated a 
protective effect of atorvastatin among patients with CKD;2 how-
ever, both the 4D trial and the primary analysis of AURORA1,3 
failed to demonstrate a benefit of statins in patients with ESRD. 
Although the secondary analysis by Holdaas et al. is encouraging, 
it must be interpreted with caution. The small signal of increased 
AADC was selectively deleted in the renal proximal tubule in 
ptAadc–/– mice. Representative photomicrographs show reduced AADC 
expression in renal proximal tubule epithelia but not in small intestine or 
brain in ptAadc–/– mice.
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stroke risk demonstrated in the 4D trial is also seen here. Further, it 
would be helpful to understand the hazard ratio for cardiac events 
among patients without diabetes mellitus. Given that the interac-
tion between treatment arm and diabetes status is significant, the 
potential that this is a biologically plausible association rather than a 
chance finding would be supported by a non-significant association 
between treatment and outcome among people without diabetes 
rather than a deleterious effect.
Lynda Szczech
1N Engl J Med 2009; 360: 1395–1407. 2Am Heart J 2010; 160: 785–794. 3N Engl J Med 2005; 
353: 238–248.
Pericyte-induced fibrosis
Göritz et al., Science 2011; 333: 238–242; doi:10.1126/science.1203165
In many chronic diseases of the kidney, the interstitial compart-
ment of this organ changes dramatically, with increased numbers 
of renal fibroblasts and the appearance of myofibroblasts (cells with 
fibroblast-like characteristics that express a-smooth muscle actin). 
It is currently thought that the marked proliferation of these cells 
and their secreted extracellular matrix is itself pathogenic, since 
they disrupt the normal renal architecture. Indeed, expansion of 
the fibro blast and myofibroblast populations and the extracellular 
matrix is tightly correlated with the slow and inexorable progressive 
loss of function that characterizes many renal diseases. Accordingly, 
the potential origin of the renal interstitial fibroblast and myofi-
broblasts has stimulated a great deal of work, from which several 
possibilities have been proposed: (1) the cells might derive from 
proliferation of resident renal interstitial fibroblasts, (2) they might 
originate by epithelial-to-mesenchymal transition, (3) they might 
originate from endothelial-to-mesenchymal transition, and (4) they 
might derive from pericytes. Clinical observations and experimen-
tal data exist to support each of these possibilities. In a recent study, 
Göritz et al. examined the role of pericytes in the origin of scar-
forming fibroblasts and myofibroblasts after spinal cord injury. They 
found that Glast-CreER transgenic mice (in which CreERT2 expres-
sion is driven by the promoter of the sodium-dependent glutamate/
aspartate transporter) allowed recombination of the R26R–yellow 
fluorescent protein (R26R-YFP) reporter allele in a subset of peri-
cytes lining capillaries in the spinal cord parenchyma, thereby stably 
and heritably labeling these cells (Figure). Because the phenotype of 
pericytes is heterogeneous and no definitive set of markers identi-
fies these cells, the demonstration by electron microscopy that the 
labeled cells are indeed pericytes and that they are a small fraction 
of these cells is of great interest. After injury, Göritz et al. found 
formation of blood vessel sprouts with associated labeled pericytes, 
but, in addition, many of these pericytes lost contact with the blood 
vessels, invaded the surrounding tissues, increased in numbers, lost 
expression of Cd13, and transiently expressed a-smooth muscle 
actin. The scar tissue generated by these pericytes was found to be 
essential to regain tissue integrity. This elegant study establishes that 
a subset of pericytes is the main source of the scar connective tissue 
in the spinal cord and thus adds support to the recent suggestion 
that renal myofibroblasts derive from renal pericytes.1
Juan Oliver
1Am J Pathol 2010; 176: 85–97.
Immune regulation:  
a macrophage subset joins  
the group of regulatory cells
Zorro Manrique et al., J Exp Med 2011; 208: 1485–1499; doi:10.1084/
jem.20100730
The identification of the transcription factor forkhead box P3 
(Foxp3) has been instrumental in identifying and characteriz-
ing regula tory T cells (Treg cells). Treg cells’ function in natural 
immune suppression has markedly altered our understanding of 
immune regulation in health and disease. Now, a study by Zorro 
Manrique et al. shows that the expression of Foxp3 by immune cells 
is not restricted to Treg cells and that a small population of Foxp3+ 
macrophages with suppressive functions can be identified. These 
CD11b+F4/80+Foxp3+ macrophages can inhibit the proliferation 
of T cells through soluble factors. Macrophages acquired Foxp3 
expression after activation, which conferred the inhibitory prop-
erties. The cytokine and transcriptional profiles of Foxp3+ macro-
phages were distinct from those of Foxp3− macrophages, indicating 
that these cells have different biological functions, including the 
induction of conversion of T cells to Treg cells. Thus, a network 
of regulatory macrophages and T cells may exist that organizes a 
concerted immune response. Further studies will have to elucidate 
the role of the new players, the Foxp3+ regulatory macrophages, in 
the maintenance of the homeostatic balance of the immune system 
with regard to tolerance, autoimmunity, organ transplantation, and 
inflammation in general. Obviously, keeping immune responses 
in check requires the cooperation of many types of immune cells, 
especially regulatory cells, including regulatory macrophages.
Detlef Schlöndorff 
Genetic labeling of a sub-population of pericytes. Electron 
micrographs showing a recombined pericyte (arrow) on a blood vessel. 
Pseudocolors indicate a recombined pericyte (green), non-recombined 
pericytes (blue), endothelial cells (red), and astrocytes (cyan). The 
inset shows the light microscopic image of the section with the same 
recombined pericyte revealed by diaminobenzidine (DAB) reaction 
(arrow) before the cutting of ultrathin sections. Lumen (asterisks).
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